[New - 7 Covid-19 Realities To Consider In 2023](https://wbbsec.com/opinions-and-features/)
[New - 7 Covid-19 Realities To Consider In 2023](https://wbbsec.com/opinions-and-features/)
powered by bulletin
In: Press Releases

For Immediate Release

March 25, 2021

Cranford, NJ – On Thursday, March 25, 2021, WBB Securities, sponsored a Demy-Colton Virtual Salon focused on the critical need for point-of-care, real-time diagnostics to address sepsis.  Sepsis, a catastrophic condition that is twice as common and twice as deadly as stroke.  Sepsis afflicts 1.7 million adults in the U.S. causing nearly 270,000 deaths. It is the largest cause of maternal deaths in the U.S. and once people recover from sepsis, they are more susceptible to subsequent septic infections. The cost of treatment for sepsis is $60 million per year to Medicare alone.  Speed is crucial in the care of sepsis, with one in three hospital deaths caused by this deadly affliction, but current diagnostic technology cannot meet the need for speed and empirical therapy is often the first intervention, usually broad-spectrum antibiotics, which are effective in only 30%-60% of cases.

Click here to watch.

About WBB Securities.

WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused primarily in the life sciences niche. Established in 2001 with offices in New Jersey, New York, and California. WBB Securities is registered with the SEC as a broker-dealer and is a member of the Financial Regulatory Authority, as well as a state registered investment advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high net-worth clients.


About Demy-Colton.

Demy Colton is a leader in biotech and life science events, with over 20 years’ experience connecting leaders of innovative biotech companies with key stakeholders, investors and advisors, we create ideal environments to examine and address opportunities and challenges in today’s biotech industry.